COMPANY
ImmunoGenesis
Timeline
- Trial start Phase 1/Phase 2: A Study of Evofosfamide in Combination with Zalifrelimab and Balstilimab source ↗
- Trial start Phase 1: Study to Evaluate IMGS-001 Treatment in Patients With Relapsed or Refractory Advanced Solid Tumors source ↗
- Trial start Phase 2: Study of TH-302 or Placebo in Combination With Pemetrexed in Patients With Non-squamous Non-small Cell Lung Cancer source ↗
- Trial start I: Phase I TH-302 Plus Gemcitabine Plus Nab-Paclitaxel in Pancreatic Cancer source ↗
- Trial start 2: A Phase 2 Biomarker - Enriched Study of TH-302 in Subjects With Advanced Melanoma source ↗
- Trial start Phase 3: Clinical Trial Testing TH-302 in Combination With Gemcitabine in Previously Untreated Subjects With Metastatic or Locally Advanced Unresectable Pancreatic Adenocarcinoma source ↗
- Trial start Phase 2: Study of the Safety and Efficacy of TH-302 in Combination With Gemcitabine Compared With Gemcitabine Alone in Previously Untreated Patients With Pancreatic Adenocarcinoma source ↗
- Trial start Phase 1/Phase 2: Dose-Escalation Study of TH-302 in Combination With Doxorubicin to Treat Patients With Advanced Soft Tissue Sarcoma source ↗
Upcoming milestones
- 2027-10 (ESTIMATED) · Phase 1/Phase 2 · A Study of Evofosfamide in Combination with Zalifrelimab and Balstilimab · NCT06782555
- 2027-12 (ESTIMATED) · Phase 1 · Study to Evaluate IMGS-001 Treatment in Patients With Relapsed or Refractory Advanced Solid Tumors · NCT06014502
Clinical trials (lead sponsor) 8
| Record | Title | Phase | Status | Start | Primary completion |
|---|---|---|---|---|---|
| NCT06014502 | Study to Evaluate IMGS-001 Treatment in Patients With Relapsed or Refractory Advanced Solid Tumors | Phase 1 | Recruiting | Sep 7, 2023 | 2027-12 (estimated) |
| NCT02093962 | Study of TH-302 or Placebo in Combination With Pemetrexed in Patients With Non-squamous Non-small Cell Lung Cancer | Phase 2 | Terminated | 2014-06 | 2016-04 (actual) |
| NCT00742963 | Dose-Escalation Study of TH-302 in Combination With Doxorubicin to Treat Patients With Advanced Soft Tissue Sarcoma | Phase 1/Phase 2 | Completed | 2008-08 | 2013-07 (actual) |
| NCT01144455 | Study of the Safety and Efficacy of TH-302 in Combination With Gemcitabine Compared With Gemcitabine Alone in Previously Untreated Patients With Pancreatic Adenocarcinoma | Phase 2 | Completed | 2010-06 | 2013-09 (actual) |
| NCT02047500 | Phase I TH-302 Plus Gemcitabine Plus Nab-Paclitaxel in Pancreatic Cancer | I | Terminated | 2014-01 | 2015-09 (actual) |
| NCT01746979 | Clinical Trial Testing TH-302 in Combination With Gemcitabine in Previously Untreated Subjects With Metastatic or Locally Advanced Unresectable Pancreatic Adenocarcinoma | Phase 3 | Completed | 2012-12 | 2016-02 (actual) |
| NCT01864538 | A Phase 2 Biomarker - Enriched Study of TH-302 in Subjects With Advanced Melanoma | 2 | Terminated | 2013-05 | 2015-09 (actual) |
| NCT06782555 | A Study of Evofosfamide in Combination with Zalifrelimab and Balstilimab | Phase 1/Phase 2 | Recruiting | Jan 8, 2025 | 2027-10 (estimated) |